Searchable abstracts of presentations at key conferences in endocrinology

ea0057012 | Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review of the literature | BES2018

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review of the literature

de Filette Jeroen MK , Joeri Pen , Brigitte Velkeniers , Kharagjitsingh Aan V

Introduction: Immune checkpoint inhibitors have revolutionized the treatment of advanced malignancies. These monoclonal antibodies target cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand (PD-L1). Endocrine side effects are common, and while hypophysitis and thyroid disorders are predominant, checkpoint-blockade associated diabetes mellitus deserves further notice.Methods: We present the case of a 61-year old male wi...

ea0099p43 | Calcium and Bone | ECE2024

The association between the ‘time to first fracture’ and imminent fracture risk – data from the FRISBEE cohort

de Filette Jeroen M.K. , Charles Alexia , Bellanger Amelie , Laura Iconaru , Baleanu Felicia , Surquin Murielle , Pierre Bergmann , Body Jean-Jacques

Background: Risk factors for fragility fractures were assessed in several prediction models (e.g. FRAX®, Garvan, FRISBEE, …). The predictors of a shorter ‘time to first fracture’ and its impact on imminent fracture risk, however, remain to be determined.Methods: The concept of ‘time to first fracture’ between inclusion in the FRISBEE cohort (‘Fracture RIsk Brussels Epidemiological Enquiry’; 3560 postmenopausal wom...